"Piperazines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
No definition found.
| Descriptor ID |
D010879
|
| MeSH Number(s) |
D03.383.606
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Piperazines".
Below are MeSH descriptors whose meaning is more specific than "Piperazines".
This graph shows the total number of publications written about "Piperazines" by people in this website by year, and whether "Piperazines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 1 | 1 |
| 1999 | 0 | 1 | 1 |
| 2000 | 3 | 0 | 3 |
| 2002 | 6 | 2 | 8 |
| 2003 | 11 | 5 | 16 |
| 2004 | 6 | 6 | 12 |
| 2005 | 4 | 7 | 11 |
| 2006 | 2 | 5 | 7 |
| 2007 | 8 | 2 | 10 |
| 2008 | 5 | 5 | 10 |
| 2009 | 7 | 8 | 15 |
| 2010 | 9 | 6 | 15 |
| 2011 | 10 | 8 | 18 |
| 2012 | 6 | 4 | 10 |
| 2013 | 5 | 5 | 10 |
| 2014 | 4 | 2 | 6 |
| 2015 | 1 | 1 | 2 |
| 2016 | 2 | 3 | 5 |
| 2017 | 6 | 2 | 8 |
| 2018 | 3 | 4 | 7 |
| 2019 | 6 | 5 | 11 |
| 2020 | 3 | 3 | 6 |
| 2021 | 6 | 6 | 12 |
| 2022 | 0 | 5 | 5 |
| 2023 | 1 | 0 | 1 |
| 2024 | 4 | 3 | 7 |
| 2025 | 1 | 4 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Piperazines" by people in Profiles.
-
DGAT1 Inhibition Enhances Olaparib-Induced Lipotoxic Apoptosis in Metastatic Castration-Resistant Prostate Cancer. FASEB J. 2025 Aug 15; 39(15):e70925.
-
Individual patient data meta-analysis of NEPA versus aprepitant-based antiemetic regimens for preventing chemotherapy-induced nausea and vomiting. Future Oncol. 2025 Sep; 21(21):2823-2833.
-
HIV Viral Rebound on Dolutegravir, Lopinavir, and Efavirenz: National Program Data Analysis From Ukraine. J Acquir Immune Defic Syndr. 2025 Aug 01; 99(4):395-404.
-
NEPA (Netupitant/Palonosetron) for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients Receiving Highly or Moderately Emetogenic Chemotherapy Who Experienced Breakthrough CINV in Cycle 1 of Chemotherapy: A Phase II Clinical Trial. Cancer Med. 2025 Apr; 14(7):e70549.
-
ZNF251 haploinsufficiency confers PARP inhibitors resistance in BRCA1-mutated cancer cells through activation of homologous recombination. Cancer Lett. 2025 Mar 31; 613:217505.
-
Palbociclib in Patients With Head and Neck Cancer and Other Tumors With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2024 Oct; 8:e2400477.
-
Abiraterone, Olaparib, or Abiraterone + Olaparib in First-Line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway). Clin Cancer Res. 2024 Oct 01; 30(19):4318-4328.
-
Palbociclib in Patients With Soft Tissue Sarcoma With CDK4 Amplifications: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2024 Jul; 8:e2400219.
-
Lasofoxifene as a potential treatment for aromatase inhibitor-resistant ER-positive breast cancer. Breast Cancer Res. 2024 06 07; 26(1):95.
-
Tumor microenvironment-induced FOXM1 regulates ovarian cancer stemness. Cell Death Dis. 2024 05 28; 15(5):370.